• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    United Therapeutic (NQ: UTHR )

    352.40 -11.15 (-3.07%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 509,068
    Open 362.37
    Bid (Size) 300.00 (1)
    Ask (Size) 356.32 (2)
    Prev. Close 363.55
    Today's Range 352.06 - 366.08
    52wk Range 208.62 - 366.08
    Shares Outstanding 44,891,523
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
    Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
    Via Investor's Business Daily
    Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga

    Performance

    YTD
    +55.00%
    +55.00%
    1 Month
    +8.19%
    +8.19%
    3 Month
    +27.56%
    +27.56%
    6 Month
    +54.06%
    +54.06%
    1 Year
    +56.46%
    +56.46%

    More News

    Read More
    United Therapeutics Corporation to Present at Upcoming Investor Conferences
    From United Therapeutics Corporation
    Via Business Wire
    Biohaven Stock Earns Relative Strength Rating Upgrade
    Via Investor's Business Daily
    SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
    Via Investor's Business Daily
    The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts
    Via Benzinga
    $100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
    Via Benzinga
    Navigating 9 Analyst Ratings For United Therapeutics
    Via Benzinga
    Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
    Via Benzinga
    ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38%
    Via Investor's Business Daily
    Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?
    Via Benzinga
    If You Invested $1000 In This Stock 20 Years Ago, You Would Have $28,000 Today
    Via Benzinga
    NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
    Via Chartmill
    3 Biotech Stocks on Track for 50% Returns (or More) by 2028
    Via InvestorPlace
    UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    United Therapeutics Stock Skids On Mixed Second-Quarter Results
    Via Investor's Business Daily
    United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
    From United Therapeutics Corporation
    Via Business Wire
    The 3 Best 3D Bioprinting Stocks to Buy Now
    Via InvestorPlace
    Beam Therapeutics Stock Earns RS Rating Jump To 85
    Via Investor's Business Daily
    United Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024
    From United Therapeutics Corporation
    Via Business Wire
    Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
    Via Benzinga
    Biotech Arvinas Stock Earns 82 RS Rating
    Via Investor's Business Daily
    Don't overlook NASDAQ:UTHR—it's a hidden gem with strong fundamentals and an attractive price tag.
    Via Chartmill
    Denali Therapeutics Stock Gets Technical Rating Upgrade
    Via Investor's Business Daily
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.